Anti‐programmed cell death protein 1 (PD‐1) and anti‐programmed cell death 1 ligand 1 (PD‐L1) therapy is another potential immunotherapy option for prostate cancer patients and has been confirmed to offer benefits to patients with melanoma, nonsmall cell lung cancer, breast cancer, and urothelial carcinoma. This evidence concerns the gene CD274 and prostate carcinoma.